Study to Evaluate the Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function
Latest Information Update: 31 May 2024
At a glance
- Drugs Chiglitazar (Primary)
- Indications Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Chipscreen Biosciences
Most Recent Events
- 24 May 2024 Status changed from recruiting to completed.
- 14 Feb 2023 Status changed from not yet recruiting to recruiting.
- 26 Aug 2022 New trial record